Biol Blood Marrow Transplant. 2011 Jul;17(7):1033-42. doi: 10.1016/j.bbmt.2010.11.003. Epub 2010 Nov 11.

A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.

Phillips GL 2nd, Bernstein SH, Liesveld JL, Abboud CN, Becker MW, Constine LS, Ifthikharuddin JJ, Loughner JE, Milner LA, Vesole DH, Friedberg JW.

Source

Hematology Oncology, University of Rochester Medical Center, James P. Wilmot Cancer Center, Strong Memorial Hospital, Rochester, New York 14642, USA. louise_haskins@umc.rochester.edu

Abstract

With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation. Between 30 July 2003 and 25 November 2008, a total of 32 lymphoma patients were entered, of which 28 were evaluable. We found the melphalan dose in BEAM could be safely escalated to at least 260 mg/m², a substantial increase from the usual dose of 140 mg/m² in BEAM while the trial was terminated early due to poor accrual, no maximal tolerated dose or dose-limiting toxicity was found. A Phase II trial is planned.

PMID:: 21074630; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Supplementary Concepts

Publication Types

MeSH Terms

Substances

Supplementary Concepts

BEAM regimen

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Lymphoma - MedlinePlus Health Information

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report. [Semin Oncol. 2004]
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Phillips GL, Abboud CN, Bernstein SH, Friedberg JW, Ifthikharuddin JJ, Lancet JE, Liesveld JL, Spreng E, Johnson V, Chapman M, et al. Semin Oncol. 2004 Dec; 31(6 Suppl 18):59-61.
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. [Br J Haematol. 2008]
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Litzow MR, Ansell SM. Br J Haematol. 2008 Oct; 143(2):268-73. Epub 2008 Aug 10.
High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. [Bone Marrow Transplant. 2004]
High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E. Bone Marrow Transplant. 2004 Oct; 34(7):581-7.
Review The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. [Semin Oncol. 2002]
Review The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
Phillips GL 2nd. Semin Oncol. 2002 Dec; 29(6 Suppl 19):53-6.
Review Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: a single center analysis and review of the literature. [Leuk Lymphoma. 2007]
Review Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: a single center analysis and review of the literature.
Strobel ES, Bauchmüller K, Ihorst G, Engelhardt M. Leuk Lymphoma. 2007 Nov; 48(11):2255-60.

See reviews... See all...

Cited by 1 PubMed Central article

High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. [Leuk Lymphoma. 2012]
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.
Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M, Milner L, Phillips G, Friedberg JW. Leuk Lymphoma. 2012 May; 53(5):830-5. Epub 2011 Dec 6.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
MedGen
Related information in MedGen
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifos...
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Biol Blood Marrow Transplant. 2011 Jul ;17(7):1033-42. doi: 10.1016/j.bbmt.2010.11.003. Epub 2010 Nov 11 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: